Kenneth W. Marshall's most recent trade in Aquestive Therapeutics Inc was a trade of 75,000 Performance Stock Units done . Disclosure was reported to the exchange on Aug. 9, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2023 | 75,000 | 75,000 | - | - | Performance Stock Units | |
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 75,000 | 75,000 | - | - | Performance Stock Units | |
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2022 | 40,000 | 40,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 80,000 | 80,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Aquestive Therapeutics Inc | Kenneth W. Marshall | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 40,000 | 40,000 | - | - | Non-Qualified Stock Option (right to buy) |